Search This Blog

Tuesday, January 28, 2020

Accuray up 15% after hours on FQ2 beat

Accuray (NASDAQ:ARAYfiscal Q2 results:
Revenue: $98.8M (-3.4%); net orders: $89.9M (+29.9%).
Backlog up 12% to $539.4M.
Net income: $10.7M (+332.6%); EPS: $0.12 (+340.0%).
Non-GAAP EBITDA: $7.1M (+73.2%).
Fiscal 2020 guidance: Revenue: $410M – 420M (unch); non-GAAP EBITDA: $21M – 26M from $19M – 24M (includes ~$1M expected loss from its JV in China).
Management does not believe that the coronavirus outbreak in China will affect the long-term demand for radiotherapy equipment there.
Shares up 15% after hours.
https://seekingalpha.com/news/3535449-accuray-up-15-after-hours-on-fq2-beat

Amphastar down 3% after hours on FDA rejection of epinephrine application

Amphastar Pharmaceuticals (NASDAQ:AMPH) slips 3% after hours in reaction to its announcement that it received a “Minor” Complete Response Letter (CRL) from the FDA regarding its marketing application for Epinephrine Injection, USP 30mg/30mL (1mg/mL) Multiple Dose.
It submitted its response yesterday and expects a decision from the agency within three months.
https://seekingalpha.com/news/3535456-amphastar-down-3-after-hours-on-fda-rejection-of-epinephrine-application

Hepion Pharma +46% on positive NASH data

Hepion Pharmaceuticals (NASDAQ:HEPA) has jumped 46% after hours after it posted positive lab data for its drug candidate for treating liver disease nonalcoholic steatohepatitis (NASH).
An expanded study with human precision cut liver slices shows that CRV431 prevented experimentally induced liver fibrosis to a greater extent than four other NASH drug candidates (obeticholic acid, elafibranor, resmetirom and Aramchol).
A Phase 1, single ascending dose study previously showed CRV431 to be safe and well tolerated in humans. Currently, CRV431 is being administered to humans in a 28-day multiple ascending dose study.
https://seekingalpha.com/news/3535512-hepion-pharmaplus-46-on-positive-nash-data

Pfizer posts 9% fall in fourth-quarter revenue

Pfizer Inc (PFE.N) reported a 9% drop in fourth-quarter revenue, hurt by intense competition for its pain treatment Lyrica that lost patent protection last year.
Revenue at the company, which is set to spin off its off-patent branded drugs business and combine it with generic drugmaker Mylan NV (MYL.O), fell to $12.69 billion from $13.98 billion a year earlier.
Net loss attributable to Pfizer narrowed to $337 million, or 6 cents per share, in the quarter, from $394 million, or 7 cents per share, a year earlier.
https://www.reuters.com/article/us-pfizer-results/pfizer-posts-9-fall-in-fourth-quarter-revenue-idUSKBN1ZR1AX

Monday, January 27, 2020

Coronavirus outbreak may disrupt Apple’s iPhone production ramp up plans

Apple Inc’s plan to ramp up iPhone production by 10% in the first half of this year may hit a roadblock as the coronavirus outbreak spreads across China, the Nikkei Asian Review reported on Tuesday.

The company has asked its suppliers, many of whom have manufacturing centers in China, to make up to 80 million iPhones in the first half of 2020, the Nikkei reported, citing people familiar with the company’s plans. (https://s.nikkei.com/2O6wXuq)
Apple has booked orders for up to 65 million of its older iPhones and up to 15 million units of a new cut-price model that it plans to unveil in March, according to the report.
However, the mass production which is due to start in the third week of February might be delayed due to the virus outbreak, the Nikkei reported.
The coronavirus outbreak has so far killed more than 100 people and infected over 4,500 in China, stranded tens of millions during the Lunar New Year holiday and rattled global markets.
Apple’s shares rose about 86% in 2019, outperforming a 29% rise in the S&P 500 index. The stock closed down nearly 3% at $308.95 on Monday as coronavirus fears dragged down high-flying U.S. chip and technology stocks.
Cupertino, California-based Apple, which raked in more than $142 billion in iPhone sales in fiscal 2019, has introduced lower priced smartphone variants to woo budget conscious shoppers and check declining sales of its biggest product category.
Last October, Nikkei reported that Apple asked its suppliers to increase production of iPhone 11 models by up to 8 million units, or about 10%, hinting that demand for the recently launched versions of its flagship phone was picking up.
The iPhone maker is set to report its first-quarter earnings after markets close on Tuesday.

https://www.marketscreener.com/APPLE-INC-4849/news/Coronavirus-outbreak-may-disrupt-Apple-s-iPhone-production-ramp-up-plans-Nikkei-29899339/?countview=0

One week sufficient for recovery from mild virus symptoms: China NHC expert

An expert at China’s National Health Commission (NHC) said on Tuesday one week is sufficient for a recovery from mild coronavirus symptoms.
The remarks were made by Li Xingwang at a press conference in Beijing, where he also said mild coronavirus symptoms do not present as pneumonia, but just slight fever.
Separately, Jiao Yahui, of the Bureau of Medical Administration at the NHC, said difficulties encountered by patients in accessing hospital beds for treating the virus have been alleviated, but protective suits are still in short supply.
https://www.reuters.com/article/us-china-health-nhc/one-week-sufficient-for-recovery-from-mild-virus-symptoms-china-nhc-expert-idUSKBN1ZR0AP

China’s Tianjin to set up dedicated hospital to treat coronavirus patients

The city of Tianjin in northern China will establish a dedicated hospital to treat people infected by the coronavirus as part of a “wartime mechanism” to fight the disease, a government-owned paper said on Tuesday, citing the local health commission.
The city will move patients in the existing Haihe hospital to make 600 beds available at any time for potential patients.
https://www.reuters.com/article/us-china-health-tianjin-hospital/chinas-tianjin-to-set-up-dedicated-hospital-to-treat-coronavirus-patients-idUSKBN1ZR036